ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

@article{Tse2008ABT263AP,
  title={ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.},
  author={Christin Tse and Alexander R. Shoemaker and Jessica Adickes and M. Anderson and J. Chen and Sha Jin and E. F. Johnson and K. Marsh and M. Mitten and P. Nimmer and L. Roberts and S. K. Tahir and Y. Xiao and X. Yang and H. Zhang and S. Fesik and S. Rosenberg and S. Elmore},
  journal={Cancer research},
  year={2008},
  volume={68 9},
  pages={
          3421-8
        }
}
  • Christin Tse, Alexander R. Shoemaker, +15 authors S. Elmore
  • Published 2008
  • Medicine
  • Cancer research
  • Overexpression of the prosurvival Bcl-2 family members (Bcl-2, Bcl-xL, and Mcl-1) is commonly associated with tumor maintenance, progression, and chemoresistance. We previously reported the discovery of ABT-737, a potent, small-molecule Bcl-2 family protein inhibitor. A major limitation of ABT-737 is that it is not orally bioavailable, which would limit chronic single agent therapy and flexibility to dose in combination regimens. Here we report the biological properties of ABT-263, a potent… CONTINUE READING
    S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth
    20
    ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo
    66
    Drugs and Clinical Approaches Targeting the Antiapoptotic Protein: A Review
    5
    The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo
    90

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 52 REFERENCES
    Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
    218
    An inhibitor of Bcl-2 family proteins induces regression of solid tumours
    2854
    The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
    1090
    Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.
    820